Tseng C C, Huang J J, Wang M C, Wu A B, Ko W C, Chen W C, Wu J J
Division of Nephrology, Department of Internal Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Kidney Int. 2007 Apr;71(8):764-70. doi: 10.1038/sj.ki.5002111. Epub 2007 Feb 7.
Most human pyelonephritogenic Escherichia coli express the PapG II adhesin. However, the role of the PapG II adhesin in enhancing the establishment and persistence of E. coli infection in the kidney is controversial. A pyelonephritogenic strain, EC114, which possesses one copy of the papG II gene, but without other virulence factors (such as S/F1C-fimbriae, hemolysin, and cytotoxic necrotizing factor 1) was selected for the construction of a papG II mutant. The resulting papG II mutant was confirmed by polymerase chain reaction, Southern hybridization, and agglutination assay, and designated as MEC114. We compared MEC114 with the parental strain (EC114) for colonization ability in the bladder and kidney of female BALB/c mice, which were challenged transurethrally with 50 microl of a low (5x10(4) CFU (colony-forming unit)) or high (5x10(8) CFU) dose of EC114 or MEC114 and assessed 1, 3, and 7 days after inoculation. Geometric means of quantitative bacterial counts in the kidney were significantly decreased when challenged with MEC114 on day 3 after inoculation, at both low and high dose (P<0.05), as compared with EC114. On the seventh day, both strains were mainly cleared from the kidney. Renal biopsy showed a similar degree of inflammatory response to both strains 1, 3, and 7 days after inoculation. In brief, the PapG II adhesin can enhance the early establishment of E. coli infection in the kidney, but the bacteria do not maintain infection owing to the host immune response.
大多数引起人类肾盂肾炎的大肠杆菌表达PapG II黏附素。然而,PapG II黏附素在增强大肠杆菌在肾脏中定植和持续存在方面的作用存在争议。选择一株肾盂肾炎致病菌株EC114,它含有一个拷贝的papG II基因,但没有其他毒力因子(如S/F1C菌毛、溶血素和细胞毒性坏死因子1),用于构建papG II突变体。通过聚合酶链反应、Southern杂交和凝集试验对所得的papG II突变体进行了确认,并将其命名为MEC114。我们将MEC114与亲代菌株(EC114)比较了在雌性BALB/c小鼠膀胱和肾脏中的定植能力,这些小鼠经尿道接种50微升低剂量(5×10⁴CFU(菌落形成单位))或高剂量(5×10⁸CFU)的EC114或MEC114,并在接种后1、3和7天进行评估。接种后第3天,当用MEC114进行低剂量和高剂量攻击时,肾脏中细菌计数的几何平均值与EC114相比显著降低(P<0.05)。在第7天,两种菌株主要从肾脏中清除。肾活检显示接种后1、3和7天对两种菌株的炎症反应程度相似。简而言之,PapG II黏附素可增强大肠杆菌在肾脏中的早期定植,但由于宿主免疫反应,细菌无法维持感染。